BUFFALO, NY--(Marketwire - January 04, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it was informed by the Department of Defense (DoD) that Protectan CBLB502, the Company’s candidate for the treatment of gastrointestinal (GI) effects of acute radiation syndrome was not selected for award under the request for proposal (RFP) No. W9113M-07-R-0002, entitled, “Medical Radiation Countermeasures Development and Delivery.”
